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Sushmita Shirish Rane 
INHIBITING GLYCOLYSIS ENHANCES T FOLLICULAR HELPER CELL 
DIFFERENTIATION AND SURVIVAL UPON HUMAN IMMUNODEFICIENCY 
VIRUS INFECTION 
Human immunodeficiency virus (HIV) primarily infects T helper (Th) cells. 
Decrease in the number of Th cells is the hallmark of HIV infection. Latent reservoirs of 
human immunodeficiency virus (HIV) are the leading barrier towards eradication of HIV 
infection. T Follicular helper (Tfh) cells are a subset of Th cells that function to provide 
aid to B cells for their maturation, affinity selection and antibody class switch. Several 
studies have shown that Tfh cells are a major reservoir of latent as well as productive hiv 
infection. But in contrast to the fate of other Th cell subsets, the frequency of Tfh cells 
was shown to have increased during HIV infection which could not be attributed to their 
reduced susceptibility to HIV infection.  
The hypothesis was that Tfh cells possess a unique metabolic phenotype that 
protects them from HIV induced cell death. Transcriptome analysis of Th subsets from 
human donors and showed that Tfh cells rely less on glycolysis for their energetic 
requirements and instead have increased transcription of fatty acid synthesis genes. This 
finding was corroborated by seahorse extracellular flux assay. The results shoId that 
glycolysis was not essential for Tfh cell differentiation in-vitro. The observed increase in 
Tfh cell frequency could not be attributed to increased Tfh differentiation upon HIV 
infection since HIV infection inhibited the differentiation of both non-Tfh and Tfh cells. 
The results found that bypassing the glycolytic pathway by providing Tfh cells with 
Galactose in the medium protected ex-vivo infected primary tonsillar cells from HIV 
vii 
induced cell death. This protection could be partly explained by the induction of 
Baculovirus IAP repeat containing 5 (BIRC5) when the cells utilized Galactose instead of 
Glucose. The studies together show that Tfh cells have an oxidative metabolic phenotype 
which protects them from HIV induced cell death in part by induction of BIRC5 
expression. 
           Quigui (Andy) Yu, MD, PhD, Chair  
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Introduction 
1.1 Human immunodeficiency virus infection 
In 1981, the Centers for Disease Control and Prevention (CDC) reported 5 cases 
of advanced unexplained immune-deficiency in homosexual men (1). This disease was 
termed as acquired immune-deficiency syndrome (AIDS). In 1983, two independent 
groups isolated the causative retrovirus which was coined as the human 
immunodeficiency virus type 1 (HIV-1, hereafter referred to as HIV) (2, 3). The HIV 
pandemic has claimed over 39 million lives, with approximately 37 million people 
worldwide living with HIV/AIDS (4), and will continue to contribute to human morbidity 
and mortality as there is no vaccine or curative treatment available. Although 
antiretroviral therapy (ART) is effective in controlling viral replication, the global 
prevalence of ART is only 59% (5). It is impossible to eliminate the HIV epidemic 
without further advancements in biomedical research of HIV infection and therapy. 
1.2. HIV life-cycle 
HIV preferentially infects activated CD4 T cells. All subtypes of CD4 T cells 
including T follicular helper (Tfh) cells are susceptible to HIV infection. HIV envelope 
(Env) protein binds to CD4 molecule on the target cell surface and undergoes 
conformational change. This conformational change allows Env to bind to one of the two 
chemokine receptors- C-X-C chemokine receptor 4 (CXCR4) or C-C chemokine receptor 
5 (CCR5). The virus enters the cells by fusion of the cell membrane and viral Env. 
Uncoating of viral capsid releases the pre-integration complex in the cytoplasm. Nuclear 
transport machinery then transports the pre-integration complex to the nucleus. Reverse 
transcription yields double-stranded complimentary viral DNA, one and two long 
2 
terminal repeat (LTR) containing circles and linear forms. The linear forms integrate into 
the host genome to become provirus. Cellular activation induces transcription from the 
provirus. Viral regulator of virion gene expression (Rev) protein transports intron-
containing viral RNAs to the cytoplasm from the nucleus. Viral structural and accessory 
proteins are generated. After virion assembly, the progeny virus is released from the 
infected cells via budding from the cell membrane (Figure 1). 
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Figure 1 
                         
 
 
Figure 1. HIV life-cycle 
HIV primarily infects CD4 T cells. Engagement of viral Env with CD4 causes 
conformational changes in the virus and allows binding to the coreceptors- CXCR4 or 
CCR5. Upon entry into the host cell, the viral reverse transcriptase converts the viral 
RNA to double stranded DNA. The pre-integration complex consists of the viral dsDNA, 
the viral integrase protein and other viral and host proteins. The pre-integration complex 
is transported into the host cell nucleus. The viral integrase integrated the HIV DNA into 
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the host genome. Viral trans-activator of transcription (Tat) facilitates transcription from 
the HIV promoter. 
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1.3 HIV infection and cellular metabolism 
Viruses are dependent on the host for provision of bioenergetics resources for the 
completion of their life cycle. Several studies have shown that viruses like hepatitis C 
virus (HCV), herpes simplex virus (HSV) and human cytomegalovirus (HCMV) alter 
host cell metabolism (6, 7). HIV replicates most efficiently in activated CD4 T cells. 
Naïve or resting CD4 T cells are resistant to HIV infection due to their inability to 
support reverse transcription as they have low reserves of nucleotides (8). Studies have 
shown that HIV infection modulates its target cells. Metabolite analysis of HIV-infected 
T cells and macrophages found that HIV infected-T cells had upregulated glycolysis. 
HIV infected macrophages in contrast had reduced Glucose uptake and glycolysis 
intermediates (9). Williamson et al demonstrated that Glucose transporters and 
hexokinase expression in T cells was dependent on viral replication and not on viral 
proteins (10). Hegedus et al showed that HIV replication and virion production requires 
glycolysis (11). Huthoff group observed that glutamine concentration was increased in 
HIV infected cells. The increased glutamine levels were redirected for the production of 
nucleotides (12). Thus, HIV life cycle is intimately dependent on the metabolism of the 
infected host cell.  
1.4 Discovery of Tfh cells 
The role of thymus in antibody immune response was demonstrated in 1965 by 
Miller (13). Thymic cells rather than the thymic niche or thymus-derived factors were 
critical for antibody producing cells(14). While studying antibody responses against 
hapten conjugated to protein carriers, Mitchison et al showed that T cells specific for the 
protein carrier provided help for maturation of hapten specific antibody producing B cells 
6 
(15). These studies together cemented the role of T cells in antibody response. Sprent 
showed that T-B cell interaction was major histocompatibility complex (MHC) class II 
restricted (16). Studies using either antigen-presenting cells (APCs) or B cells lacking 
MHC class II molecules confirmed that T cell help to B cells requires T cell recognition 
of peptide-MHC II complexes(17). Several groups demonstrated that T helper cells 
expressing the CXC chemokine receptor 5 (CXCR5) localized to B cell follicles and 
provided help for B cell maturation (18-20). These studies first coined the term T 
follicular B helper (Tfh) cells. 
1.5 Phenotype of human Tfh cells 
Three studies independently showed that B-cell lymphoma 6 (Bcl6) is an essential 
transcription factor for Tfh cell differentiation but not essential for differentiation of other 
T helper cell subsets (21-23). Gene expression studies of human Tfh cells revealed that 
several genes including Interleukin -21 (IL-21), programmed death-1 (PD-1), CXCR5, 
Bcl6, and inducible T cell co-stimulator (ICOS) were upregulated in Tfh cells. 
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Figure 2 
 
       
                     
Figure 2. Phenotype of human Tfh cells 
Tfh cells are defined as CD4 T cells expressing surface markers CXCR5, PD-1 
and ICOS, the transcription factor Bcl6 and secretion of the cytokine IL-21. 
(Craft JE, 2012 Follicular helper T cells in immunity and systemic autoimmunity, 
Nat.Rev. Rheum, 8.6:337-358)  
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1.6 Tfh cell differentiation 
Differentiation of Tfh cells is a multistage multi-factorial process. The multi-
signal process of Tfh differentiation accommodates heterogeneity. The process of Tfh 
cell differentiation can be divided into three stages-priming, commitment to Tfh cell fate 
at the B and T cell border of the germinal center (GC) and full polarization. The 
differentiation process starts by initial priming of naïve T cells by dendritic cells (DCs). 
Human DCs have been shown to induce differentiation of IL-21-producing Tfh-like cells 
that are capable of inducing antibody production by B cells. DCs induced differentiation 
of IL-21-producing Tfh cells through IL-12. Bcl6 expression is upregulated after TCR 
activation. Early induction of Bcl6 was observed as soon as 2-4 days in the absence of B 
cells. However, there was a significant reduction in Tfh differentiation by day 8 in 
absence of B cells. This indicates that even though DCs are able to transiently induce 
early differentiation of Tfh cells, antigen presentation by B cells is important to sustain 
Tfh differentiation in vivo. 
Extensive studies in humans have shown that multiple cytokines contribute 
towards Tfh differentiation – mainly TGF-β, IL-12 and IL-23 (24). Activated human CD4 
T cells cultured in the presence of IL-12 or IL-23 showed increased expression of the Tfh 
markers - CXCR5, ICOS and Bcl6. In addition, the combination of the cytokines IL-12 
and TGF- β induced the highest expression of Tfh markers on activated CD4 T cells. 
Activin A, a member of the TGF-β superfamily, in combination with IL-12 was also 
shown to drive Tfh cell differentiation in vitro (25).  
The migration of Tfh cells to B cell follicles enables the critical step of B cell 
dependent stage of Tfh differentiation. Interaction with ICOSL expressed on activated B 
9 
cells is essential for Tfh cell differentiation. ICOS induced phospho-inositol 3 kinase 
(PI3K) activation regulated expression of Tfh derived effectors like IL-21 and CD40. 
Two phenotypically well-defined populations of Bcl6-expressing Tfh cells are 
identified in mice as well as humans. These are referred to as Tfh and GC Tfh cells. GC 
Tfh cells are further differentiated Tfh cells that express the highest levels of Bcl6 and 
CXCR5 in human tonsillar CD4 T cells. It is currently unclear whether GC Tfh are the 
terminally differentiated cells or whether they can alternate between the GC Tfh and Tfh 
phenotypes. 
1.7 Functions of Tfh cells   
Tfh cells provide help for B cell maturation and affinity maturation . Tfh cells are 
essential for the formation and maintenance of GCs, for generation of memory B cells 
and plasma cells.CD40L is highly expressed on activated T cells, while CD40 is a co-
stimulatory protein found on the surface of APCs. CD40-CD40 ligand (CD40L) signaling 
is important for sustenance of GC B cells. CD40-CD40L interaction provides survival 
signals to the highly apoptotic GC B cells. 
PD-1 is an inhibitory receptor for T cells. Interaction of PD-1 with its ligands PD-
L1 or PD-L2 prevents T cells from killing the target cells. Recent studies have shown that 
PD-1 drives the localization of Tfh cells in the B cell follicles of the GCs (26). Studies 
with PD-1 deficient mice have shown that PD-1 is critical for maintenance of GC B cells. 
In PD-1 deficient mice, lesser number of long-lived plasma cells were observed. PD-1 
deficiency also resulted in reduced expression of IL-21 and IL-4 (27). 
ICOS deficiency in humans resulted in severe reduction of memory B cells and 
abrogated antigen specific IgG response to vaccines (28). 
10 
IL-4 was shown to be highly expressed in GC Tfh cells independent of Th2 
differentiation (29, 30). IL-4 provides anti-apoptotic signals to B cells inducing 
expression of the anti-apoptotic Bcl2 (31). 
IL-21 drives plasma cell differentiation. IL-21 induces expression of the master 
transcription factor of plasma cells - Blimp1 via STAT3 (32). 
Humans Tfh cells express high levels of CXCL13, the ligand for CXCR5. 
CXCL13 may enhance the recruitment of B cells to the GCs (33). 
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Figure 3       
 
 
Figure 3. Function of Tfh cells 
 Tfh cells provide help to B cells for B cell affinity maturation and antibody class 
switching by cell-cell interactions via cell membrane factors like CD40-CD40L, ICOS 
and PD-1 and also through soluble effectors like IL-4 and IL-21. 
(Craft JE, 2012 Follicular helper T cells in immunity and systemic autoimmunity, 
Nat.Rev. Rheum, 8.6:337-358) 
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1.8 Tonsillar Tfh cells vs blood CXCR5+ T helper cells 
Tissue Tfh cells have an activated T cell phenotype (CD45RO-) whereas CXCR5+ 
T helper cells in the periphery have a memory T cell phenotype CD45RO+. One 
hypothesis to explain this phenomenon states that peripheral CXCR5+ Th cells are 
memory Tfh cells. However, a study using gene expression profiling found that there 
were significant differences in the gene expression profiles of the two populations (34). 
The study found differences in expression of several functional families of genes 
including transcription factors, cytokines and co-stimulatory molecules. Tonsillar Tfh 
cells have higher expression of Notch and Wnt signaling molecules compared to 
peripheral blood Tfh cells. IL-7 receptor and IL-10Rα were highly expressed on 
peripheral blood Tfh cells but downregulated in tonsillar Tfh cells (34) 
1.9 Tfh cell dynamics during HIV infection 
Soon after the discovery of HIV-1, studies have shown that GCs act as reservoirs 
of HIV-1 (35, 36). Like other T helper cell subsets, Tfh cells are susceptible to HIV-1 
infection and support production of HIV-1 virions (35). Follicular DCs are thought to be 
responsible for entrapment of HIV-1 and spread to Tfh cells (37). Perreau et al showed 
that CXCR5+PD-1+ and CXCR5-PD-1+ cells isolated from chronically HIV-1 infected 
patients were enriched in HIV-1 specific CD4 T cells. They also showed that the Tfh 
population was the most efficient in supporting HIV-1 replication and virion production. 
In addition, they also observed that replication-competent HIV-1 could be isolated from 
Tfh cells from patients on ART with low viremia (<1,000 HIV-1 RNA copies) (38). 
Therefore, they concluded that Tfh cells act as a major reservoir of HIV-1.  
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Tfh cell frequency was also shown to expand during HIV-1 infection even after 
ART (39). Hong et al enumerated Tfh cells per unit area of lymph nodes of SIV infected 
macaques and observed approximately 4-fold increase in absolute Tfh cell numbers (40). 
This study indicates that during chronic HIV infection there is an increase in absolute 
numbers of Tfh cells instead of a slower decline in cell number. This observation is in 
contrast to the studies that show that HIV-1 infection causes massive loss of infected cells 
due to cell death. The decrease in total CD4 count is the hallmark of HIV-1 infection.  
Chronic HIV-1 infection also leads to severe dysregulation of B cell immune 
response. In healthy individuals, most B cells in the periphery have naïve or memory B 
cell phenotype. In HIV-1 infected individuals, alterations in the B cell phenotypes are 
observed in peripheral blood. B cell subpopulations including immature transitional B 
cells, activated mature B cells and plasmablasts are observed at a higher frequency in 
HIV-1 infected patients compared to healthy individuals (41). HIV infection induced 
immune cell activation is a hallmark of HIV pathogenesis. B cell hyper-activation during 
HIV infection is characterized by hypergammaglobulinemia (42). HIV infection directly 
or indirectly causes B cell activation. HIV proteins such as gp120 and Nef have been 
proposed to affect B cell activation. Binding of gp120 to C type lectins on B cells induces 
antibody class switching (43). By inducing infected macrophages to produce pro-
inflammatory cytokines, Nef drives polyclonal B cell activation (44). HIV infection also 
directly affects B cell activation by affecting Tfh cell function. Cubas et al observed that 
the frequency of PD-L1+ GC B cells in HIV-infected individuals was higher compared to 
uninfected individuals. Engagement of PD-1 on Tfh cells with PD-L1 on B cells resulted 
in reduced expression of ICOS and IL-21 (45). 
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1.10 Metabolism in immune cells 
Immune response against environmental stress requires cell proliferation and 
secretion of effector molecules such as cytokines, chemokines and inflammatory 
mediators. This process is bio-energetically expensive and requires cells to adapt by 
switching their metabolic programming. All cells produce adenosine triphosphate (ATP) 
to maintain their basic cellular functions. The bioenergetics needs of cells are fulfilled by 
interconnected pathways of glycolysis, tricarboxylic acid (TCA) cycle and oxidative 
phosphorylation (OXPHOS). Glycolysis is an anaerobic process that occurs in the 
cytoplasm. Cells uptake Glucose from the environment through Glucose transporters. 
Once entered into the cells, Glucose is phosphorylated to Glucose 6-phosphate by 
hexokinases. Sequential glycolytic process yields two molecules each of pyruvate, 
NADH and ATP. Glucose 6-phosphate produced during glycolysis can enter the pentose 
phosphate pathway (PPP) that generates riboses which are the building blocks of RNA 
and DNA. 
Under normoxic conditions, pyruvate is oxidized to yield ATP and NADH via the 
TCA cycle. In hypoxic conditions, pyruvate is reduced to lactate and NAD+. NADH 
produced via the TCA cycle acts as a reducing agent in the oxidative phosphorylation 
pathway to generate ATP. During oxidative phosphorylation, sequential electron transfer 
in redox reactions releases energy which is utilized to produce ATP. Carbohydrates, 
amino acids and fatty acids can enter the TCA cycle by their conversion into acetyl-
coenzyme A. Complete oxidation of Glucose by the TCA cycle and OXPHOS yields 
approximately 30-36 ATP molecules. Thus, in aerobic conditions, oxidative metabolism 
is a bioenergetically favorable pathway for ATP production. 
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Glycolysis and TCA cycle also provide intermediates for the biosynthesis of 
riboses, fatty acids and non-essential amino acids. Some tumor cells display preferential 
reliance on glycolysis in aerobic conditions even though it is energetically unfavorable. 
This process of aerobic glycolysis is known as the Warburg effect. Some tumor cells use 
Glucose to suppress OXPHOS. This event is known as the “Crabtree effect”. 
Adaptive immune cells have the unique features of antigen-specific proliferation 
to establish and maintain a pool of antigen specific memory cells. Antigen driven 
proliferation of adaptive immune cells requires a metabolic phenotype that provides for 
the synthesis of DNA, proteins, membranes and organelles. The quiescent memory cells 
require a metabolic phenotype that supports their long-term survival. 
The energy needs of naïve CD4 T cells are fulfilled by oxidation of Glucose and 
fatty acids (46). Stimulated T cells proliferate in response to the antigen and produce 
effector molecules like cytokines. The metabolic requirements of T cells increase 
dramatically upon activation. Activated T cells fulfill this demand by increasing 
glutamine and Glucose metabolism while suppressing fatty acid oxidation. Studies have 
shown that glycolysis is upregulated in mitogen-stimulated peripheral T lymphocytes 
(47). Nutrient insufficiency prevents T cell activation. Jacobs et al show that Glucose 
metabolism induced by CD28 signaling is essential for T cell activation (48). The 
metabolic programming of activated T cells is regulated at the transcriptional and post-
transcriptional stage. Activated CD4 T cells differentiate into distinct subsets based on 
the cytokine milieu. The metabolic phenotype of T effector subsets – Th1, Th2, Th17 and 
regulatory T (Treg) cells is well characterized. Studies have shown that the kinase 
mammalian target of rapamycin (mTOR) plays crucial role in T helper cell 
16 
differentiation. mTOR forms two complexes-rapamycin sensitive mTORC1 and the 
rapamycin insensitive mTORC2. mTORC1 signaling upregulates aerobic glycolysis in T 
cells. mTOR deficient T cells are able to differentiate only into Treg subset (49). 
Inhibiting mTORC1 signaling suppresses Th1 and Th17 differentiation but does not 
affect Th2 differentiation. In contrast, inhibiting mTORC2 signaling inhibits Th17 
differentiation but not Th1 or Th17. In-vitro differentiated Th1, Th2 and Th17 cells 
exhibit increased glycolysis compared to naïve T cells whereas Tregs display elevated 
rates of lipid oxidation (50). 
Studies in mice have shown that mTORC1 and mTORC2 induced glycolysis is 
sufficient to induce Tfh cell differentiation (51). In contrast, Ray et al have shown that 
Tfh cells display reduced glycolysis and mitochondrial respiration as a result of reduced 
mTORC1 activity when compared to Th1 cells (52). IL-2 induced mTORC1 activity and 
increased glycolysis was sufficient to drive Th differentiation away from Tfh lineage. 
Oestrich et al showed that Bcl6 binds to the promoters of glycolysis genes like Glucose 
transporter 1 (Glut1), Glucose transporter 3 (Glut3), hexokinase 2 and pyruvate kinase M 
(PKM) and represses their transcription.  When Bcl6 expression vector was transfected 
into primary Th1 cells cultured in a high concentration of IL-2, Bcl6 was able to repress 
gene expression of glycolysis genes. These studies show that Bcl6 is able to repress 
glycolytic gene expression even if the culture conditions are favorable for the pathway. 
PD-1, a marker of Tfh cells, was shown to alter T cell metabolic programming. 
Patsoukis et al showed that engagement of PD-1 with its ligand PD-L1 induced increased 
expression of genes involved in fatty acid oxidation. They showed that this metabolic 
programming aided the long-term survival of T cells (53). 
17 
Although the metabolic requirements for Tfh cell differentiation are well defined, 
the metabolic phenotype of human tonsillar cells has not been studied yet.  
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Figure 4  
 
 
Figure 4. Metabolic pathways in immune cells 
Major metabolic pathways in an immune cell are glycolysis, the TCA cycle and 
oxidative phosphorylation.  
During glycolysis, Glucose taken up via Glucose transporter 1 (Glut1) is 
phosphorylated by hexokinase and sequentially processed to yield pyruvate and 2 ATPs. 
Glycolysis intermediates can be used to produce riboses via the pentose phosphate 
pathway. Pyruvate is redirected to the mitochondria and enters the TCA cycle after 
reduction to acetyl CoA. Fatty acid oxidation (FAO) can also fuel the TCA cycle by 
providing acetyl CoA. NADH produced by the TCA cycle is passed through the electron 
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transport chain and undergoes OXPHOS to yield 3-36 molecules of ATP. Pyruvate is 
converted to lactate that is excluded from the cells. 
(modified from-MacIver NJ, Michalek RD, Rathmell JC.2013. Metabolic 
regulation of T lymphocytes. Annu Rev Immunol 31:259-283)  
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Figure 5  
a) 
                                
 
b) 
 
 
Figure 5. Metabolic phenotype of T cell stages and T helper cell subsets 
a) Naïve T cells display a dependency on OXPHOS to meet their metabolic requirements. 
Upon activation, several signals including CD28 engagement trigger switch from 
OXPHOS to glycolysis. Activated T cells also have enhanced glutaminolysis. Upon 
resolution of the immune response, activated T cells convert to the quiescent memory T 
21 
cells which rely on fatty acid oxidation as the main source of energy. Memory T cells 
also have increased mitochondrial number.    
b) mTOR kinases induce aerobic glycolysis in effector Th subsets- Th1, Th2 and Th17. 
AMPK induces FAO in Tregs and in memory T cells. 
(modified from-MacIver NJ, Michalek RD, Rathmell JC.2013.Metabolic regulation of T 
lymphocytes. Annu Rev Immunol 31:259-283) 
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Figure 6       
 
           
Figure 6. Bcl6 inhibits glycolysis when overexpressed in Th1 cells 
IL-2 induces switch from fatty acid oxidation and oxidative phosphorylation to 
aerobic glycolysis by upregulating expression of cellular Myc (c-Myc) and Hypoxia-
inducible factor 1–alpha (HIF1-α). TCR engagement also maintains aerobic glycolysis. 
Bcl6 inhibits T box containing protein expressed in T cells (Tbet) induced expression of 
glycolysis genes. 
(Modified from – Kevin Man and Axel Kallies.2014. Bcl-6 gets T cells off the 
sugar, Nat Immunol, 15:904-905) 
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1.11 Hypothesis 
Tfh cells have been shown to be major reservoirs of HIV (38). The frequency and 
absolute numbers of Tfh cells were shown to have expanded in patients chronically 
infected with HIV. The expansion of Tfh cell frequency may be attributed to their 
reduced susceptibility to HIV infection. The question whether this increase in Tfh cells in 
HIV patients is due to increased differentiation or reduced rate of HIV-induced cell death 
of infected cells is yet unanswered. Considering the unique niche of Tfh cells in the GCs, 
we hypothesized that Tfh cells have a unique metabolic phenotype that aids in their 
survival upon HIV infection. The four specific aims to test this central hypothesis are 
Aim 1 – the metabolic phenotype of Tfh cells. 
Aim 2 – metabolic requirements for human Tfh cell differentiation in-vitro 
Aim 3 – effect of HIV infection on Tfh cell differentiation 
Aim 4 – Survival of Tfh cells as a function of their metabolic phenotype. 
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Materials and Methods 
2.1. Isolation of primary tonsillar T cells 
Fresh tonsil tissue samples were obtained from the Indiana tissue bank in 
complacency with the IU IRB. Single cell suspensions were prepared from the tissue 
sample (how?). Mononuclear cells were isolated from the single cell suspension using 
Ficoll Hypaque density gradient centrifugation (GE Healthcare bioscience, Uppsala, 
Sweden). CD19+B cells and CD8+T cells were depleted from the mononuclear cells 
using positive magnetic separation beads. In brief, tonsillar mononuclear cells were 
incubated with CD19 and CD8 magnetic beads (Miltenyi, Bergisch Gladbach, Germany) 
on ice for 30 minutes. After 30 minutes of incubation, labelled CD19+B cells and CD8+T 
cells were depleted using a magnet. The enriched tonsillar T cells were counted using a 
hemocytometer and resuspended in RPMI supplemented with 10%FBS and 1% 
Penicillin, Streptamycin and L-glutamate (cRPMI).  
2.2. Sorting of primary tonsillar T cells 
Enriched tonsillar T cells were stained with CD4-FITC (SK3), CXCR5-APC 
(MU5UBEE) and PD-1-PECY7 (EH12.2H7). After 30 minutes of incubation at 4°C, 
cells were washed twice with PBS containing 2% bovine serum Fetal. Stained tonsillar T 
cells were gated on their expression of CD4. CD4 T cells were sorted into four 
populations based on their expression of CXCR5 and PD-1 using FACS ARIA sorter as 
shown in Figure 1a. The four populations were GC Tfh (CD4+CXCR5hiPD-1hi), 
CD4+CXCR5-PD-1+, CD4+CXCR5+PD-1- and CD4+CXCR5-PD-1-. 
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2.3. RNA sequencing of tonsillar T cells 
Total RNA was extracted from sorted tonsillar T cells using Pure Link RNA 
microkit (Invitrogen, Carlsbad, California) (please indicate resources of all reagents or 
kits) according to the kit protocol. RNA sequencing was performed at the Indiana 
University School of Medicine center for Medical Genomics. RNA concentration and 
quality was assessed using Agilent 2100 Bioanalyzer. Dual indexed strand specific cDNA 
library was prepared using KAPA mRNA Hyperprep kit. Quality and concentration of 
the prepared cDNA library was determined using Qubit and Agilent 2100 Bioanalyzer. 
Two hundred picomolar pooled libraries were utilized per flowcell for clustering 
amplification on cBot using HiSeq 3000/4000 PE Cluster kit and sequenced with 2X75 
bp configuration on Illumina HiSeq 4000 using HiSeq 3000/4000 PE SBS kit. The 
sequenced libraries were mapped to the hg38 human genome using STAR RNA-seq 
aligner. Uniquely mapped sequencing reads were assigned to hg38 human genome using 
featureCounts. Differential expression analysis was performed using edgeR. 
2.4. Isolation of naive human T cells and in-vitro Tfh differentiation 
Buffy coat samples were obtained from healthy donors from Indiana Blood Bank 
(Indianapolis, IN). PBMCs were separated using Ficoll Hypaque (GE Lifesciences) 
density gradient centrifugation. Naive T cells were isolated from PBMCs using Human 
CD4 Naive T cell isolation kit (Biolegend, San Diego, CA). Isolated naive T cells were 
activated with human T cell activation beads (anti-CD3/anti-CD28; Life Technologies, 
Carlsbad, CA) for 24 hours. After 24 hours of activation, activated CD4 T cells were 
transferred into anti-CD3 coated wells and cultured in Glucose free complete RPMI 
(supplemented with 10% FBS and 100 U/ml of penicillin/streptomycin/glutamine) 
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supplemented with either 10 mM of D-Glucose or D-Galactose (Thermo Fisher, 
Waltham, Massachusetts) for 4 days. The cells were treated with 1 ng/ml IL-12 
(Biolegend, San Diego, California) and 5 ng/ml TGF-β (Biolegend, San Diego, 
California)or 1 ng/ml IL-12 and 50 ng/ml Activin A (Minneapolis, Minnesota) for Tfh 
polarization or 10 ng/ml IL-12 and 1000 U/ml IL-2 (Biolegend, San Diego, California) 
for Th1 polarization. 
2.5. HIV-1 NL4.3 Viral stock preparation 
HIV-1 NL4.3 full length replication and infection competent chimeric DNA was 
obtained from NIH AIDS reagents program (NIAID, Bethesda, DC). The plasmids were 
transformed and expanded in One Shot Top10 chemically competent E.coli. Plasmids 
were extracted using Qiaprep midi kit. 18 micrograms of pNL4.3 was transfected into 
HEK293T cells in a T75 flask. Cell supernatant was collected 48 hours after transfection. 
The cell supernatant was filtered through a 0.2-micron filter and purified by 
centrifugation. Virus stock was titrated by measuring the concentration of HIV core 
protein using HIV-1 p24 ELISA kit (XpressBio, Frederick, MD) 
2.6. In-vitro HIV infection 
For infection of in-vitro differentiated T cells with HIV-1, the differentiated cells 
were incubated with HIV-1 NL4.3 at the concentration of 20 ng/ml HIV p24 at 37oC for 
4 hours. After the incubation, cells were washed thrice and cultured in Glucose-free 
complete RPMI  
For HIV infection before Tfh differentiation, the isolated naive Tfh cells were 
activated with human T cell activation beads (anti-CD3/CD28; Life Technologies, 
Carlsbad, CA) for 24 hours. The activated cells were incubated with HIV NL4.3 virus at 
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the concentration of 20 ng/ml of p24. After incubation with the virus at 37oC for 4 hours, 
the activated cells were transferred into anti-CD3 coated wells and cultured in Glucose-
free cRPMI supplemented with 10 mM Glucose or Galactose for 4 days. The cells were 
treated with 1 ng/ml IL-12 and 5 ng/ml TGF-β or 1 ng/ml IL-12 and 50 ng/ml Activin A 
for Tfh polarization or 10 ng/ml IL-12 and 1000 U/ml IL-2 for Th1 polarization. 
2.7. Antibodies and flow cytometry 
Fluorophore-conjugated monoclonal antibodies against human CD4 (SK3,SK4), 
CXCR5 (MU5UBEE), PD-1 (EH12.2H7), HIV p24 (KC57), and BIRC5 (91630) were 
purchased from BioLegend (San Diego, CA) or BD Pharmingen (San Jose, CA). Fixable 
Viability Dye ef780 from eBiosciences (San Diego, CA) was used as a marker for 
live/dead cells. 
Cells were subjected to surface staining first by incubating the cells with 
antibodies against human CD4, CXCR5 and PD-1 at 4°C for 30 minutes. After 
incubation, the cells were washed twice with PBS containing 2% FBS. The cells were 
then incubated with fixable viability dye ef780 diluted 1:1,000 in PBS at room 
temperature for 15 minutes. The cells were washed twice with PBS. For intracellular 
staining, the cells were permeabilized using BD Cytofix/CytoPerm Buffer for 30 minutes 
at room temperature. After fixing, the cells were washed twice with BD Perm wash 
buffer. The cells were then incubated with antibodies against HIV p24 or human BIRC5 
at 4°C for 30 minutes. The cells were then washed twice with PBS containing 2% FBS. 
The cells were then analyzed using LSR4 flow cytometer. Flow cytometry data was 
analyzed using FlowJo software (FlowJo LLC, Ashland, Oregon 
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2.8. Determining mitochondrial mass of T cells  
In-vitro differentiated T cells or isolated tonsillar T cells were subjected to cell 
surface staining and live/dead staining as previously described. The cells were then fixed 
with 2% PFA at room temperature for 30 minutes. The cells were washed twice with PBS 
containing 2% FBS. The cells were then incubated with Mito ID Green (Enzo Life 
Sciences, Farmingdale NY) diluted 1:2,000 in the assay buffer provided for 20 minutes at 
room temperature. The cells were then immediately acquired on the LSR4 flow 
cytometer. 
2.9. Seahorse assay 
Tonsillar T cells were sorted as described above. The cells were cultured 
overnight in cRPMI. The sensor cartridge was hydrated overnight with 200 µl per well of 
sterile water. After overnight hydration, the sensor cartridge was calibrated using 200 µl 
per well of Agilent seahorse XF calibrant and incubating for 1 hour at 37°C in a non-CO2 
incubator. The seahorse XF96 cell culture miniplates were coated with Cell Tak 
(Corning, Corning New York) at the concentration of 22.4 ng/ml. The plate was 
incubated for 15 minutes at 37°C in a non-CO2 incubator. After 15 minutes, the wells 
were washed with sterile water. The cells were counted using a hemocytometer and 
resuspended in RPMI (without FBS and antibiotics) at the concentration of 1 million 
cells/ml. 200 µl of cell suspension was added to each well so that each well had 0.2 
million cells. The cell culture miniplates were incubated at 37°C in a non-CO2 incubator. 
The compounds- Oligomycin, Antimycin A, Rotenone and Carbonyl cyanide-4 
(trifluoromethoxy) phenylhydrazone (FCCP) were purchased from Cayman biologicals 
(Ann Arbor, Michigan). The compounds were diluted to the concentrations of 100 µM 
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for Oligomycin, 500 µM for FCCP and 100 µM each for Antimycin A and Rotenone. 
The compounds were added to the sample injection ports as instructed by the 
manufacturer so that the final concentrations of the compounds in the assay were - 10 µM 
for Oligomycin, Antimycin A and Rotenone and 50 µM for FCCP. The assay was 
performed on a seahorse Xf96 extracellular flux analyzer (Agilent, Santa Clara, 
California). The results were normalized and analyzed using the wave software (Agilent, 
Santa Clara, California). 
2.10. Statistical analysis 
Statistical analysis was performed using Graphpad prism 6 software (GraphPad 
software, San Diego, California). Student’s t test was used for comparison between two 
groups. 
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Results 
3.1. RNA sequencing revealed differential expression of metabolism genes 
To unravel the difference in metabolic gene expression between follicular and 
non-follicular CD4 T cells, we performed transcriptome sequencing on human tonsillar 
CD4 T cells. CD4 T cells were isolated from tonsils of three HIV-1-negative donors who 
had undergone otolaryngoscopic surgery. Tonsillar CD4 T cells were then sorted based 
on their expression of CXCR5 and PD-1 into four subpopulations including CXCR5-PD-
1-, CXCR5-PD-1+, GC Tfh (CXCR5hiPD-1hi) and CXCR5+PD-1 (Figure a). Sorted 
cells were subjected to RNA extraction for RNA-seq analysis. Transcriptome analysis 
revealed that there was difference in the expression of metabolic genes compared 
between GC Tfh and CXCR5-PD-1- cells. GC Tfh cells showed reduced expression of 
genes associated with glycolysis when compared to CXCR5-PD-1- cell population. 
Instead, GC Tfh cells had increased expression of genes involved in fatty acid oxidation 
and gluconeogenesis (Figure 7c). Gene ontology analysis revealed that genes associated 
with fatty acid oxidation were the most enriched group in GC Tfh cells (Figure 7d). 
These results indicate that Tfh cells are less reliant on glycolysis for their energy 
requirements. 
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Figure 7  
a) 
 
 
b)                                                                                      
                                   
c) 
 
 
  
 
d) 
                         
Figure 7. RNA sequencing revealed differential expressions of metabolism genes 
a) Representative flow plots showing the gating strategy for the sorting of tonsillar      
CD4T cells. Tonsillar CD4T cells were sorted into four populations based on their 
expression of CXCR5 and PD-1. 
CXCR5- PD-1- 
CXCR5- PD1+  
CXCR5+PD-1- 
GC TFH 
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b) Volcano plot showing differential gene expression between GC Tfh and CXCR5-PD-
1- tonsillar T cells. 
c)  Heatmap showing differential gene expression of metabolic genes between GC Tfh 
and other tonsillar CD4 T cell subsets.  
d) KEGG pathway analysis of differentially expressed metabolic genes in GC Tfh cells.  
  
  
  
33 
3.2. Seahorse assay revealed oxidative metabolic phenotype of Tfh cells 
RNA sequencing data revealed that Tfh cells have lower expression of glycolytic 
genes when compared to non-Tfh cells. To confirm the metabolic phenotype of Tfh cells, 
I performed Seahorse extracellular flux assay with sorted tonsillar CD4T cell subsets.  
Seahorse extracellular flux assay measures oxygen consumption rate (OCR) and 
extracellular acidification rate (ECAR) of live cells at intervals of approximately 5-8 
minutes. The OCR is a measure of mitochondrial respiration and ECAR is indicative of 
the rate of glycolysis. The Seahorse mito-stress test was performed to determine the 
metabolic phenotype of tonsillar CD4 T cells and to analyze the parameters of 
mitochondrial function.  In the mito-stress test, several respiration modulating 
compounds are added to the assay to reveal mitochondrial functional dynamics. 
Oligomycin inhibits ATP synthase (complex V), and is injected first in the assay 
following basal measurements. It reduces electron flow through the ETC, resulting a 
reduction in mitochondrial respiration or OCR. This decrease in OCR is linked to cellular 
ATP production. Carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone (FCCP) is an 
uncoupling agent that collapses the proton gradient and disrupts the mitochondrial 
membrane potential. It is the 2nd injection following Oligomycin. As a result, electron 
flow through the ETC is uninhibited, and oxygen consumption by complex IV reaches 
the maximum. The FCCP-stimulated OCR can then be used to calculate spare respiratory 
capacity, defined as the difference between maximal respiration and basal respiration. 
Spare respiratory capacity is a measure of the ability of the cell to respond to increased 
energy demand or under stress. The third injection is a mixture of rotenone, a complex I 
inhibitor, and antimycin A, a complex III inhibitor. This combination shuts down 
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mitochondrial respiration and enables the calculation of non-mitochondrial respiration 
driven by processes outside the mitochondria.  
Seahorse mito-stress test revealed that GC Tfh cells have higher basal oxygen 
consumption rate when compared to other tonsillar CD4 T cell subsets (Figure 8a, b). GC 
Tfh cells also had higher spare respiratory capacity, maximal oxygen consumption rate 
and ATP production from respiration as compared to other tonsillar CD4 T cell subsets 
(Figure 8c, d, e)  
These results verify that Tfh cells have reduced reliance on glycolysis and exhibit 
oxidative metabolic phenotype. 
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Figure 8  
a) 
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Figure 8. Seahorse assay revealed oxidative metabolic phenotype of Tfh cells 
 a) Graph showing Oxygen consumption rate over time and compound injection strategies. 
 b) Basal oxygen consumption rates for tonsillar CD4 T cell subsets.  
 c) Spare respiratory capacity of tonsillar CD4 T cell subsets. 
 d) Maximal respiration of tonsillar CD4 T cell subsets. 
 e) ATP production associated with respiration for tonsillar CD4 T cell subsets 
    Data is represented as mean ± SEM of 5 replicates. 
b) c) 
d) 
) 
e) 
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d) Maximal respiration of tonsillar CD4 T cell subsets. 
e) ATP production associated with respiration for tonsillar CD4 T cell subsets 
    Data is represented as mean ± SEM of 5 replicates. 
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3.3. Galactose yielded higher frequency of Tfh cells 
 To determine if glycolysis is necessary for in-vitro differentiation of Tfh cells, we 
differentiated Tfh cells in either Glucose- or Galactose-containing medium. After 4 days 
of differentiation, we determined Tfh cell frequency using flow cytometry. 
The results show that Galactose medium yielded higher frequency of Tfh cells 
compared to Glucose medium (Figure 9a, 9b). The absolute number of CXCR5+PD-1+ 
cells was also higher in Galactose medium (1,770 ± 1.9 SEM, n=) compared to Glucose 
medium (755 ± 0.8 SEM, n=) (Figure 9c). 
I compared the two previously described methods for in-vitro differentiation of 
Tfh cells (24, 25). Without addition of polarizing cytokines, we observed minimal 
frequency of Tfh cells (Figure 9d). The results found no significant difference in Tfh cell 
frequency when we compared the Tfh yield between the two methods (p = 0.1, n=4) 
(Figure 9d) 
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Figure 9 
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Figure 9. Galactose yielded higher frequency of Tfh cells 
a) Representative flow plots showing Tfh cell frequencies upon in-vitro differentiation 
in Glucose or Galactose containing medium. 
 
 
 
b) 
c) 
d) 
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b) Graphical representation of Tfh cell frequencies upon in-vitro differentiation in 
glucose and galactose containing medium. 
c) Graphical representation of Tfh cell numbers upon in-vitro differentiation in glucose or 
galactose containing medium. 
d) Graphical representation of the comparison between the two approaches for in-vitro 
Tfh differentiation. 
Data is represented as mean ± SEM of five (IL-12+TGF-β) or four (IL-12+Activin A) 
independent experiments. Student’s t test was used to analyze data. **p≤0.01, ns-not 
significant. 
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3.4. Mitochondrial mass was comparable between Tfh and non-Tfh cells 
To determine if the increased use of OXPHOS in Tfh cells was due to increase in 
mitochondrial mass, I first differentiated naïve human CD4 T cells into either Tfh, Th1 or 
non-polarized (Th0) cells and then stained the cells with MitoID Green. MitoID Green 
stains the mitochondria independent of the mitochondrial membrane potential and is used 
to measure the mitochondrial mass (54). I observed no difference in MitoID Geen 
fluorescence intensity when I compared between Tfh, Th1 and Th0 cells (Figure 10a and 
b). 
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Figure 10 
a) 
 
 
 
 
 
 
 
b)  
                                                
Figure 10. Mitochondrial mass was comparable between Tfh and non-Tfh cells 
a)Representative flow plots showing mean fluorescence intensity (MFI) of MitoID green 
in in-vitro differentiated Th0, Th1 and Tfh cells.  
b)Graphical representation of MitoID Green MFI in in-vitro differentiated Th0, Th1 and 
Tfh cells. 
Data is represented as mean ± SEM of 2 independent experiments.  
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3.5. HIV Infection reduced differentiation of Tfh and non-Tfh cells 
I hypothesized that HIV infection affects Tfh cell differentiation dependent on the 
cell’s metabolism. For the study, we activated naïve T cells for 24 hours. After activation, 
the cells were incubated with HIV-1 NL4.3 strain equivalent to 20 ng/ml p24 for 4 hours. 
The cells were then incubated with Tfh polarizing cytokines for 4 days and then Tfh cell 
frequency was assessed by flow cytometry. I found that in uninfected condition, 
Galactose yielded higher frequency of Tfh cells. HIV infection abrogated in-vitro Tfh 
differentiation in both Glucose and Galactose condition (Figure 11a). The reduction in 
Tfh cell frequency after HIV infection was significantly higher in Glucose condition 
compared to that in Galactose condition (Figure 11b). HIV infected cells were quantified 
by staining with antibodies against HIV p24. I found that HIV p24+ cell frequency was 
higher in Galactose than in Glucose condition (Figure 11c, 4d)  
These results indicate that though there is a higher frequency of HIV infected 
cells in the Galactose condition, it did not result in significant reduction of Tfh cell 
frequency as compared to Glucose condition. 
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Figure 11. HIV Infection reduced differentiation of Tfh and non-Tfh cells 
a) Representative dot plots depicting Tfh cell frequencies after in-vitro differentiation 
upon HIV infection. 
 
b) Representative dot plots showing HIV-1 p24 expression in infected Tfh cells. 
Figure 11 
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b) Representative dot plots showing HIV p24 expression in infected Tfh cells. 
c)Graphical representation of the reduction of Th frequency after HIV infection in Glucose and Galactose medium 
           d)Graphical representation of the HIV p24+ T cells in Glucose and Galactose medium. 
Data is represented as mean ± SEM of 4 independent experiments. Student’s t test was used for statistical analysis. *p<0.05 
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3.6. Ex-vivo tonsillar CD4 T cell subsets expressed CD69 but were resistant to HIV 
infection unless activated 
I wanted to examine whether the survival of primary tonsillar T cells upon HIV-1 
infection was dependent on their metabolic phenotype. I isolated tonsil tissue CD4 T cells 
from HIV-negative donors. The isolated CD4 T cells were either activated with anti-
CD3/anti-CD28 beads or mock-activated with PBS and followed by infection with HIV-1 
NL4.3 equivalent to 100 ng/ml p24. The cells were cultured in Glucose or Galactose 
containing medium for 4 days. After four days the cells were analyzed for viability and 
HIV p24. I observed that tonsillar CD4 T cells could be divided into five populations 
based on their expression of CXCR5 and PD-1 (Figure 12a) as described previously. 
When I looked at the activation markers such as CD25, CD38, CD69 and HLA-DR 
expression on tonsillar T cells I found that there was minimal expression of activation 
markers CD25, CD38 and HLA-DR. Whereas I found that there was high frequency of 
tonsillar CD4 T cell subsets expressed CD69 (Figure 12b). I next wanted to examine 
whether CD69 expression alone was sufficient to allow HIV-1 infection. The results 
showed that un-activated tonsillar CD4 T cells were resistant to HIV-1 infection, 
although they were CD69-positive (Figure 12c). 
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Figure 12 
a)                                   
 
 
 
 
 
 
 
 
 
                                 
 
Figure 12. Ex-vivo tonsillar CD4 T cell subsets expressed CD69 but were resistant to 
HIV infection unless activated 
a) Representative dot plots showing tonsillar CD4T cell subsets based on their expression 
of CXCR5 and PD-1.  
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b) CD69 expression on tonsillar CD4 T cell susets. 
c) Graphical representation showing HHIV-1 p24+ T cells among the tonsillar CD4 T 
cell subsets. 
Data is represented as mean ± SEM of three independent experiments. Student’s t test 
was used for statistical analysis. ***p≤0.001 
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3.7. HIV infected ex-vivo tonsillar T cells survive better in Galactose medium 
I next assessed survival of infected tonsillar CD4 T cells in Glucose versus 
Galactose medium. I found that upon HIV infection, the frequency of viable tonsillar 
CD4 T cells was higher in Galactose medium compared to Glucose medium (Figure 13b). 
When I looked at the frequency of HIV-1-infected cells, I observed that the frequency of 
HIV p24-positive cells was higher in Galactose medium compared to Glucose medium 
(Figure 13c). These results indicate that HIV-infected tonsillar CD4 T cells survived 
better in Galactose medium compared to Glucose medium despite of having higher 
frequencies of HIV-infected cells. 
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Figure 13  
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Figure 13. HIV infected ex-vivo tonsillar T cells survive better in Galactose medium 
a) Representative dot plots showing frequencies of tonsillar CD4 T cell subsets cells upon 
HIV-1 infection 
b) Graph showing HIV-1 p24+ CD4 T cells on day0 and day 4 after HIV-1 infection 
cultured in Glucose or Galactose medium. 
 
a) 
b) c) 
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cultured in Glucose or Galactose medium. 
c) Graph showing frequency of live HIV-1 infected tonsillar CD4T cells on day 0 and 
day 4 post HIV-1 infection cultured in Glucose or Galactose medium. 
Data is represented as mean ± SEM of 3 independent experiments. Student’s t test was 
used for statistical analysis. ***p≤0.001 
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3.8. BIRC5 expression was upregulated in CD4 T cells cultured in Galactose 
medium upon HIV infection 
A recent study has shown that the expression of Baculoviral IAP repeat 
containing protein 5 (BIRC5) is upregulated in CD4 T cells latently or productively 
infected with HIV. Inhibition of BIRC5 resulted in reduced frequency of HIV infected 
CD4 T cells with intact HIV DNA (58). The transcriptome sequencing analysis revealed 
that expression of several anti-apoptotic genes was higher in GC Tfh cells (Figure 14a). 
Interestingly the expression of BIRC5 was about 23-fold higher in GC Tfh compared to 
CXCR5-PD-1- cells. I studied whether expression of BIRC5 was dependent on the cells’ 
metabolism. I cultured HIV infected tonsillar T cells in Glucose or Galactose medium 
and measured the expression of BIRC5 using flow cytometry. I found that expression of 
BIRC5 was higher in Galactose medium even in the mock infected cells. The expression 
of BIRC5 was further upregulated on HIV infected tonsillar T cells cultured in Galactose 
medium compared to Glucose. The results suggest that the enhanced survival of infected 
Tfh cells in Galactose medium can be partly explained by the upregulation of BIRC5. 
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Figure 14  
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Figure 14. BIRC5 expression was upregulated in CD4 T cells cultured in 
Galactose medium upon HIV infection 
a) Heatmap showing differential gene expression of apoptosis related genes among 
tonsillar CD4 T cells. 
b) c) 
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b) Representative flow-cytometry plots showing BIRC5 MFI on HIV-1 infected tonsillar 
CD4 T cells 4 days post infection. 
c) Graph showing BIRC5 MFI on HIV-1 infected tonsillar T cells on day 4 post infection. 
Data is represented as mean ± SEM of 3 independent experiments. Student’s t test was 
used for statistical analysis.     
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Discussion 
Tfh cells have been shown to be susceptible to HIV infection. Tfh cells serve as 
major reservoirs of latent and productive HIV infection even upon ART. In contrast to 
the fate of other CD4 T cell subsets, Tfh cell frequency was shown to have increased 
during HIV infection. The expansion of Tfh cells during HIV infection may be due to 
increased differentiation of Tfh cells or due to their increased survival. 
Transcriptome analysis of tonsillar CD4 T cells revealed differential expression of 
metabolism genes between Tfh and non-Tfh cells. Specifically, Tfh cells had higher 
expression of genes involved in fatty acid oxidation and gluconeogenesis whereas non-
Tfh cells had higher expression of glycolysis genes. Gene set enrichment analysis showed 
that Tfh cells displayed a phenotype that resembles naïve T cells. Based on the gene 
expression analysis, the hypothesizes was that Tfh cells have unique metabolism that 
drives their differentiation and survival upon HIV infection. 
I first studied the metabolic pathway necessary for Tfh cell differentiation. I 
differentiated activated CD4 T cells into Tfh cells in the presence of Glucose or 
Galactose to drive the cells to use either glycolysis or OXPHOS, respectively. The results 
indicate significantly higher frequency of Tfh cells when the cells were differentiated in 
Galactose containing medium. The results reflect the studies by Xie et al (55). They 
showed that Glucose depletion mediated induction of 5’- Adenosine monophosphate 
activated protein kinase (AMPK) induces expression of Bcl6 in activated CD4 T cells in 
mice. The studies together indicate that glycolysis is not necessary for Tfh differentiation 
in-vitro. 
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I next studied the effects of HIV infection and metabolism on Tfh differentiation. 
I found that HIV infection reduced Tfh differentiation in both Glucose and Galactose 
medium. This reduction in Tfh cell frequency was significantly higher in Glucose 
medium. 
Several cell intrinsic and extrinsic factors could contribute to the decreased 
differentiation of Tfh cells upon HIV infection. IL-12 is crucial for Tfh differentiation in 
humans. Marshall et al have shown that HIV-1 infection caused dysfunction of IL-12 
signaling in PBMCs. They showed that HIV infected PBMCs have reduced expression of 
the IL-12 receptor β chain (IL-12R β)(56). TGF-β levels are increased during HIV 
infection but immune cells are refractory to the effect of TGF-β. George et al showed that 
the expression of transforming growth factor B and mothers against decapentaplegic 
homolog 5 (SMAD5), a TGF-β signal transduction molecule is downregulated during 
SIV infection (57). Depletion of cytokines that drive Tfh polarization during HIV 
infection may contribute towards reduced Tfh differentiation. 
The next aim was to next study if the survival of infected Tfh cells was dependent 
on their metabolism. The results showed that HIV infected tonsillar Tfh cells survive 
better upon HIV infection when cultured in Galactose medium. Transcriptome analysis 
revealed that Tfh cells express higher levels of the anti-apoptotic molecule-BIRC5. 
BIRC5 protects cells against extrinsic and intrinsic pathways of apoptosis by directly 
inhibiting the activation of caspase 9. Expression of BIRC5 and its upstream regulator - 
tumor necrosis factor receptor superfamily member 4 (TNFRSF4, also known as OX40), 
were shown to have increased during HIV infection (58). OX40 plays a critical role in 
long-term survival of memory T cells (59). Kuo et al also show that OX40+ CD4 T cells 
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isolated from HIV infected patients had higher clonally expanded HIV-1 DNA compared 
to OX40- CD4 T cells (58). These results indicate that OX40+ CD4 T cells act as viral 
reservoirs. The increased BIRC5 expression in HIV-infected Tfh cells in Galactose 
condition may thus play a role in their enhanced survival and contribute to maintain viral 
reservoir in Tfh cells. Whether the oxidative phenotype of Tfh cells is an effect of 
increased BIRC5 expression is unclear and needs further studying. Strikingly, 
pharmacological inhibition of BIRC5 reduced the number of infected cells harboring 
intact viral DNA. Therefore, BIRC5 is a viable target for elimination of viral reservoirs in 
Tfh cells. 
In addition to cell intrinsic factors, cell extrinsic factors such as the concentration 
of ART drugs in the lymph nodes and cytotoxicity of HIV specific CD8 T cells in the 
lymph nodes also play important roles in the survival of HIV infected Tfh cells. 
Fletcher et al have shown that lymphatic tissues have lower concentration of ART 
drugs compared with peripheral blood (60). The low concentration of  ART drugs in the 
lymph nodes is the cause for persistent viral replication observed in the lymph nodes.  
Li et al show that SIV-specific CD8 T cells were excluded from the GCs. They 
also showed that the frequency of follicular CD8 T cells was inversely correlated with 
viral RNA-positive cells (61). Therefore, in addition to targeting BIRC5, strategies to 
increase concentration of ART drugs in the lymph nodes and improving CD8 cytotoxicity 
in the GCs are critical for elimination of infected Tfh cells. 
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Future directions 
The results indicate that Tfh cell differentiation does not require glycolysis. HIV 
infection reduces Tfh differentiation in Glucose and Galactose medium but this reduction 
is significantly higher in Glucose medium. The results show that HIV infected Tfh cells 
survive better in Galactose medium. This enhanced survival may be due to upregulation 
of the anti-apoptotic BIRC5 in Galactose medium. 
Cells cultured in Galactose medium show increased OXPHOS. Several pathways 
including fatty acid oxidation and amino acid metabolism contribute towards increased 
OXPHOS. Studies with fatty acid oxidation inhibitors or amino acid metabolism 
inhibitors are required to further dissect the pathway important for Tfh cell 
differentiation. Inhibiting glycolysis using 2 deoxy-Glucose will further confirm the 
contribution of glycolysis in Tfh differentiation. 
Tfh cells are characterized by their expression of the transcription repressor Bcl6 
and by their ability to secrete IL-21. I plan to study the expression of Bcl6 and IL-21 in 
the in-vitro differentiated Tfh-like cells to validate their Tfh phenotype. 
Metabolic phenotype of a cell can be measured by quantifying the extracellular 
proton concentration and their oxygen consumption rate. The seahorse extracellular flux 
assay measures the proton concentration as an indicator of the rate of glycolysis and 
oxygen consumption rate as the rate of OXPHOS. Seahorse extracellular flux assays with 
sorted tonsillar CD4T cells and in-vitro differentiated Tfh cells to define their metabolic 
phenotype should be repeated to get a solid understanding. 
Studies have shown that the GC microenvironment is hypoxic (62). Currently, we  
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culture the cells in normoxic conditions. Culturing Tfh cells under hypoxic conditions 
will closely mimic their in-vivo niche. Culturing the Tfh cells under hypoxic conditions 
will lead to better understanding their metabolism under physiological conditions. 
The main role of Tfh cells is to provide help to B cells for antibody production. 
Several studies have shown that the humoral response in dysregulated during HIV 
infections indicating defects in Tfh cell functions. I plan to study how metabolism 
contributes to Tfh cell function. For this purpose, we will incubate Tfh cells with 
autologous B cells in Glucose or Galactose medium and measure the quantity and isotype 
of the secreted antibodies. 
The results show that infected Tfh cells have higher levels of BIRC5. BIRC5 
plays a role in the survival of memory T cells. We plan to use the BIRC5 inhibitor, 1-(2-
Methoxyethyl)-2-methyl-4, 9-dioxo-3-(pyrazin-2-ylmethyl)-4, 9-dihydro-1H-naphtho [2, 
3-d] imidazolium bromide (YM155) to study its effect on HIV infected Tfh cells in 
context of their metabolism. YM155 suppresses transcription from the BIRC5 promoter. 
Studies have shown that YM155 is specific against BIRC5 and has no effect on other 
inhibitors of apoptosis family members (IAPs). If upregulation of BIRC5 is important in 
survival of infected Tfh cells, inhibition of BIRC5 should reduce the survival of the 
infected Tfh cells. 
CD8 T cells in the follicle kill HIV infected Tfh cells. To determine whether 
metabolism affects CD8 T cell response to infected HIV Tfh cells. We plan to co-culture 
HIV infected Tfh cells in Glucose or Galactose medium labelled with radioactive 
chromium isotope with autologous CD8 T cells.  
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A better understanding of mechanism contributing towards maintaining Tfh cells 
as HIV reservoirs will help in devising strategies for elimination of HIV reservoirs. 
Eradication of cellular HIV reservoirs will ultimately lead to an HIV cure. 
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